Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2007 May;151(2):161-2.
doi: 10.1038/sj.bjp.0707164. Epub 2007 Mar 20.

Optimisation of anti-psychotic therapeutics: a balancing act?

A J Lawrence  1
Affiliations
Comment

Optimisation of anti-psychotic therapeutics: a balancing act?

A J Lawrence. Br J Pharmacol. 2007 May.

Abstract

Schizophrenia is a complex and debilitating disorder. Although effective therapeutic strategies are available, these are not without problems and are not universally efficacious. In this issue of the British Journal of Pharmacology, a trio of papers describe the characterisation of a potential, novel anti-psychotic medication, F15063. This compound combines antagonism of dopamine D(2)-like receptors with agonism at 5-HT(1A) receptors. Based on in vitro and in vivo profiles, the authors suggest that this compound approaches the 'optimal balance' for activity at these receptor systems.

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Depoortère R, Bardin L, Auclair AL, Kleven M, Prinssen E, Newman-Tancredi A.F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: activity in models of positive symptoms of schizophrenia Br J Pharmacol 2007a151253–265.this issue - PMC - PubMed
    1. Depoortère R, Auclair AL, Bardin L, Bruins Slot L, Kleven M, Newman-Tancredi A.F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: activity in models of cognition and negative symptoms Br J Pharmacol 2007b151266–277.this issue - PMC - PubMed
    1. Hall J, Whalley HC, Job DE, Baig BJ, McIntosh AM, Evans KL, et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci. 2006;9:1477–1478. - PubMed
    1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223. - PubMed
    1. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science. 2005;310:1187–1191. - PubMed

MeSH terms

Substances